Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis.

Abstract:

Background:Melatonin (MLT), a kind of neuroendocrine active substance, has been reported to function in the treatment of tumors. However, there remain controversies about the curative effect of MLT in tumors in clinical studies. This study investigates the efficacy of MLT on tumor therapeutic strategies by meta-analysis. Methods:After searching several main literature databases, a total of 5,057 articles were obtained and screened by inclusion and exclusion criteria. The tumor remission rate, overall survival rate, and incidence of side effects were recorded and analyzed in the included study patients. Group analysis and sensitivity analysis were performed to examine the sources of heterogeneity in the pooled studies. Results:The tumor remission rate in the MLT group was significantly higher than that in the control group (relative risk [RR] =2.25; 95% CI, 1.86-2.71; P<0.00001; I2=9%). Likewise, the MLT group had an overall survival rate of 28.24% (n=294/1,041), which was greatly increased compared with the control group (RR =2.07; 95% CI, 1.55-2.76; P<0.00001; I2=55%). And, MLT could significantly enhance the overall survival rate in non-small-cell lung cancer patients (RR =2.13; 95% CI, 1.41-3.24; P=0.0004; I2=0%) and various solid tumor patients (RR =2.31; 95% CI, 1.78-2.99; P<0.00001; I2=0%). It was further proved that MLT could effectively reduce the incidence of neurotoxicity (RR =0.30, 95% CI, 0.19-0.45; P<0.00001), thrombocytopenia (RR =0.23; 95% CI, 0.16-0.33; P<0.00001), and asthenia (RR =0.43, 95% CI, 0.38-0.49; P<0.00001) during chemotherapy. Conclusion:MLT exerts positive influence in tumor therapeutic strategies, including improving tumor remission rate and overall survival rate, while reducing the incidence of chemotherapy side effects. Further large-scale randomized clinical trials (RCTs) are urgently required to verify therapeutic effects of MLT in tumors by various clinical research centers.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Wang Y,Wang P,Zheng X,Du X

doi

10.2147/OTT.S174100

subject

Has Abstract

pub_date

2018-11-08 00:00:00

pages

7895-7908

issn

1178-6930

pii

ott-11-7895

journal_volume

11

pub_type

杂志文章
  • Profile of abemaciclib and its potential in the treatment of breast cancer.

    abstract::Hormone-receptor-positive breast cancer is the most common subtype of breast cancer among patients with both early-stage and metastatic disease. Recent advances in the understanding of its pathophysiology have led to the discovery and utilization of targeted inhibitors to cyclin-dependent kinases 4 and 6 (CDK4/6). The...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S149245

    authors: Martin JM,Goldstein LJ

    更新日期:2018-08-29 00:00:00

  • FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC.

    abstract:Objective:As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, an overwhelming majority of these patients inevitably develop resistance against gefitinib. Unfortunately, th...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S220462

    authors: Zhang D,Han LL,Du F,Liu XM,Li J,Wang HH,Song MH,Li Z,Li GY

    更新日期:2019-11-18 00:00:00

  • Bone Marrow Stromal Antigen 2 is a Potential Unfavorable Prognostic Factor for High-Grade Glioma.

    abstract:Background:Bone marrow stromal antigen 2 (BST2) is considered as a transmembrane glycoprotein and plays essential roles in innate immunity. It has been recently reported that up-regulation of BST2 was associated with the development of breast carcinoma. However, the clinical significance of BST2 in glioma has not been ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S258631

    authors: Shi H,Luo K,Huang W

    更新日期:2020-08-26 00:00:00

  • Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.

    abstract::Ovarian cancer (OC) is the most lethal cancer of all gynecological malignancies, while endometrial cancer (EC) is the most common one. Current strategies for OC/EC diagnosis consist of the extraction of a solid tissue from the affected area. This sample enables the study of specific biomarkers and the genetic nature o...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S227156

    authors: Chen Q,Zhang ZH,Wang S,Lang JH

    更新日期:2019-12-27 00:00:00

  • MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor.

    abstract::MicroRNAs (miRs) have been demonstrated to play key roles in the development and progression of hepatocellular carcinoma (HCC). However, the regulatory mechanism of miR-503 in HCC has not been fully uncovered. In this study, we found that miR-503 was significantly downregulated in HCC tissues compared to nontumorous l...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S106351

    authors: Xiao Y,Tian Q,He J,Huang M,Yang C,Gong L

    更新日期:2016-06-15 00:00:00

  • Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology.

    abstract::Pleiotropy in biological systems and their targeting allows many pharmaceuticals to be used for multiple therapeutic purposes. Fully exploiting the therapeutic properties of drugs that are already marketed would be highly advantageous. This is especially the case in the field of oncology, where the ineffectiveness of ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S182685

    authors: Papanagnou P,Papadopoulos GE,Stivarou T,Pappas A

    更新日期:2018-12-31 00:00:00

  • A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.

    abstract:BACKGROUND AND PURPOSE:Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer. However, diarrhea i...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S96830

    authors: Huo Z,Yu S,Hong S,Cao X,Xiu L,Liao Z,Li Y,Xiao H

    更新日期:2016-06-20 00:00:00

  • Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence.

    abstract::The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal translocation involving the NTRK gene family occur across a wide range of cancers in both children and adults. Preclinical studies have demonstrated that chimeric p...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S177051

    authors: Ricciuti B,Genova C,Crinò L,Libra M,Leonardi GC

    更新日期:2019-04-30 00:00:00

  • The Protective Effect of Testosterone on the Ovarian Reserve During Cyclophosphamide Treatment.

    abstract:Introduction:Cyclophosphamide, which is widely used to treat malignant disease, causes ovarian follicular atresia, which leads to premature ovarian insufficiency. The present study evaluated the protective effect of testosterone in preventing the decline in the ovarian reserve during cyclophosphamide treatment. Method...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S242703

    authors: Yoo M,Tanaka T,Konishi H,Tanabe A,Taniguchi K,Komura K,Hayashi M,Ohmichi M

    更新日期:2020-04-08 00:00:00

  • Significance of tertiary Gleason pattern 5 in patients with Gleason score 7 after radical prostatectomy: a retrospective cohort study.

    abstract:Purpose:To evaluate the association between tertiary Gleason pattern 5 (TGP5) and biochemical recurrence (BCR) in patients with prostate cancer (PCa) with a Gleason score (GS) of 7 after radical prostatectomy (RP). Patients and methods:This retrospective study identified 350 patients who received RP and were graded as...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S218001

    authors: Li J,Guo Y,Qiu S,He M,Jin K,Zheng X,Tu X,Liao X,Yang L,Wei Q

    更新日期:2019-09-02 00:00:00

  • SOX5 promotes cell invasion and metastasis via activation of Twist-mediated epithelial-mesenchymal transition in gastric cancer.

    abstract:Background:Sex-determining region Y-box protein 5 (SOX5) has been demonstrated to be implicated in oncogenic function in various types of cancers. However, the role of SOX5 in gastric cancer (GC) remains poorly elucidated. Herein, we investigated the role and the underlying mechanism of SOX5 in GC progression. Methods...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S197087

    authors: You J,Zhao Q,Fan X,Wang J

    更新日期:2019-04-03 00:00:00

  • Effects of magnetic nanoparticles of Fe3O4 combinated with gambogic acid on apoptosis of SMMC-7721 cells.

    abstract:OBJECTIVE:This study aims to investigate the potential benefit of combination therapy with magnetic nanoparticles of Fe3O4 (Fe3O4-MNP) and gambogic acid (GA) on SMMC-7721 cells. METHODS:The inhibition of proliferation of SMMC-7721 cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assa...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S86494

    authors: Tian L,Chen BA,Cheng J,Guo QL

    更新日期:2015-08-26 00:00:00

  • MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1.

    abstract::Purpose: Numerous microRNAs (miRNAs) are aberrantly expressed in breast cancer, and the dysregulation of miRNAs may affect the aggressiveness of this cancer. Aberrant expression of miRNA-937 (miR-937) in gastric and lung cancers has been reported, which plays tumor-suppressive or oncogenic roles in carcinogenesis incl...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S207593

    authors: Han X,Guo X,Zhang W,Cong Q

    更新日期:2019-06-20 00:00:00

  • Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.

    abstract:Background:Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S159777

    authors: Wang K,Ruan H,Xu T,Liu L,Liu D,Yang H,Zhang X,Chen K

    更新日期:2018-05-28 00:00:00

  • Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.

    abstract:Purpose:Circular RNAs (circRNAs) are emerging as promising biomarkers for various human malignancies. However, the application of circRNAs as non-invasive biomarkers in high-grade serous ovarian cancer (SOC) remains to be elucidated. Here, we aim to investigate the feasibility of using serum circSETDB1, a tumor-promoti...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S220700

    authors: Wang W,Wang J,Zhang X,Liu G

    更新日期:2019-09-11 00:00:00

  • Profile of selumetinib and its potential in the treatment of melanoma.

    abstract::The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential d...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S51596

    authors: Kim DW,Patel SP

    更新日期:2014-09-19 00:00:00

  • Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis.

    abstract:BACKGROUND:The purpose of this study was to evaluate clinical outcomes of conventional fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas (HCCs) without portal vein tumor thrombosis. METHODS:Patients with up to four HCC lesions not treatable by surgery or percutaneous ablative ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S69618

    authors: Jung J,Kong M,Hong SE

    更新日期:2014-09-26 00:00:00

  • Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data.

    abstract::This study aimed to identify the genes and pathways associated with smoking-related lung adenocarcinoma. Three lung adenocarcinoma associated datasets (GSE43458, GSE10072, and GSE50081), the subjects of which included smokers and nonsmokers, were downloaded to screen the differentially expressed feature genes between ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S114230

    authors: Liu Y,Ni R,Zhang H,Miao L,Wang J,Jia W,Wang Y

    更新日期:2016-12-07 00:00:00

  • Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.

    abstract:PURPOSE:Subsets of non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs; erlotinib, gefitinib, and icotinib) in patients with non-small-cell lung cancer carrying insertions ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S108242

    authors: Chen D,Song Z,Cheng G

    更新日期:2016-07-08 00:00:00

  • Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma.

    abstract::Background: CD19-directed chimeric antigen receptor (CAR) T cells have substantial benefit in the treatment of patients with B-cell malignancies. However, despite encouraging therapeutic efficiency, there is limited overall response rate when anti-CD19 CAR-T cells are used to treat patients with relapsed and refractor...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S198567

    authors: Li S,Xue L,Wang M,Qiang P,Xu H,Zhang X,Kang W,You F,Xu H,Wang Y,Liu X,Yang L,Wang X

    更新日期:2019-07-12 00:00:00

  • Update on oncolytic viral therapy - targeting angiogenesis.

    abstract::Oncolytic viruses (OVs) have the ability to selectively replicate in and lyse cancer cells. Angiogenesis is an essential requirement for tumor growth. Like OVs, the therapeutic effect of many angiogenesis inhibitors has been limited, leading to the development of more effective approaches to combine antiangiogenic the...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S46974

    authors: Tysome JR,Lemoine NR,Wang Y

    更新日期:2013-07-31 00:00:00

  • Onivyde for the therapy of multiple solid tumors.

    abstract::Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S105587

    authors: Zhang H

    更新日期:2016-05-20 00:00:00

  • High expression of HMGA2 predicts poor survival in patients with clear cell renal cell carcinoma.

    abstract::High-mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors, but its role in renal carcinoma remains unclear. The aim of this study was to examine the expression of HMGA2 and its relationship to the overall survival (OS) of patients with non-metasta...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S116953

    authors: Na N,Si T,Huang Z,Miao B,Hong L,Li H,Qiu J,Qiu J

    更新日期:2016-11-22 00:00:00

  • ADAMTS8 Inhibits Cell Proliferation and Invasion, and Induces Apoptosis in Breast Cancer.

    abstract:Introduction:A disintegrin and metallopeptidase with thrombospondin motifs (ADAMTSs), whose expression is dysregulated in various cancers, is implicated in cancer development. Herein, we aimed to investigate the functional role of ADAMTS8 in breast cancer (BC) and explore the underlying mechanisms. Methods:The protein...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S248085

    authors: Zhang K,Tian R,Wang G,Zhang J,Ma H,Hu X,Xi J,Wang G

    更新日期:2020-08-21 00:00:00

  • Different setup errors assessed by weekly cone-beam computed tomography on different registration in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.

    abstract::The study aimed to investigate the difference of setup errors on different registration in the treatment of nasopharyngeal carcinoma based on weekly cone-beam computed tomography (CBCT). Thirty nasopharyngeal cancer patients scheduled to undergo intensity-modulated radiotherapy (IMRT) were prospectively enrolled in th...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S87159

    authors: Su J,Chen W,Yang H,Hong J,Zhang Z,Yang G,Li L,Wei R

    更新日期:2015-09-14 00:00:00

  • Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms.

    abstract::Gastrointestinal stromal tumor (GIST) is an uncommon mesenchymal tumor, and has been shown to be associated with synchronous or metachronous second malignancies. Rare cases of coincident GIST and non-Hodgkin lymphomas (NHL) have been reported previously. Here, we report two cases of GIST and coincident primary breast ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S159843

    authors: Ludmir EB,Gutschenritter T,Pinnix CC,Gunther JR,Nastoupil LJ,Khoury JD,Medeiros LJ,Dabaja BS,Milgrom SA

    更新日期:2018-12-10 00:00:00

  • Association of estrogen receptor α PvuII and XbaI polymorphisms with prostate cancer susceptibility and risk stratification: a meta-analysis from case-control studies.

    abstract:BACKGROUND:Studies on the association between two single nucleotide polymorphisms (SNPs) in estrogen receptor α (ERα), PvuII (rs2234693 T>C) and XbaI (rs9340799 A>G), and the prostate cancer risk are inconsistent. Therefore, we performed a meta-analysis to derive a more accurate estimation of this relationship. METHOD...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S132419

    authors: Zhao Y,Zheng X,Zhang L,Hu Q,Guo Y,Jiang H,Shi S,Zhang X

    更新日期:2017-06-29 00:00:00

  • Clinical analysis of 13 males with primary choriocarcinoma and review of the literature.

    abstract:OBJECTIVE:To analyze the management and prognosis of primary choriocarcinoma (PCC) in male patients. METHODS:The clinical records of males with PCC who were treated at Peking Union Medical College Hospital between 1990 and 2012 were analyzed retrospectively. The literature regarding this clinical condition was also re...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S62561

    authors: Jiang F,Xiang Y,Feng FZ,Ren T,Cui ZM,Wan XR

    更新日期:2014-06-20 00:00:00

  • Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review.

    abstract:Background:Intra-abdominal desmoplastic small round cell tumor (IADSRCT) is a highly invasive malignant tumor that is rare in clinical practice. Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) ...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S190333

    authors: Chen HM,Feng G

    更新日期:2018-12-18 00:00:00

  • Ipilimumab in the treatment of metastatic melanoma: management of adverse events.

    abstract::Recently, "ipilimumab," an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. "CTLA-4" is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTL...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S57335

    authors: Della Vittoria Scarpati G,Fusciello C,Perri F,Sabbatino F,Ferrone S,Carlomagno C,Pepe S

    更新日期:2014-02-19 00:00:00